Cargando…

New insights into the mode of action of the lantibiotic salivaricin B

Salivaricin B is a 25 amino acid polycyclic peptide belonging to the type AII lantibiotics and first shown to be produced by Streptococcus salivarius. In this study we describe the bactericidal mode of action of salivaricin B against susceptible Gram-positive bacteria. The killing action of salivari...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbour, Abdelahhad, Tagg, John, Abou-Zied, Osama K., Philip, Koshy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985645/
https://www.ncbi.nlm.nih.gov/pubmed/27526944
http://dx.doi.org/10.1038/srep31749
_version_ 1782448093817470976
author Barbour, Abdelahhad
Tagg, John
Abou-Zied, Osama K.
Philip, Koshy
author_facet Barbour, Abdelahhad
Tagg, John
Abou-Zied, Osama K.
Philip, Koshy
author_sort Barbour, Abdelahhad
collection PubMed
description Salivaricin B is a 25 amino acid polycyclic peptide belonging to the type AII lantibiotics and first shown to be produced by Streptococcus salivarius. In this study we describe the bactericidal mode of action of salivaricin B against susceptible Gram-positive bacteria. The killing action of salivaricin B required micro-molar concentrations of lantibiotic whereas the prototype lantibiotic nisin A was shown to be potent at nano-molar levels. Unlike nisin A, salivaricin B did not induce pore formation or dissipate the membrane potential in susceptible cells. This was established by measuring the fluorescence of the tryptophan residue at position 17 when salivaricin B interacted with bacterial membrane vesicles. The absence of a fluorescence blue shift indicates a failure of salivaricin B to penetrate the membranes. On the other hand, salivaricin B interfered with cell wall biosynthesis, as shown by the accumulation of the final soluble cell wall precursor UDP-MurNAc-pentapeptide which is the backbone of the bacterial peptidoglycan. Transmission electron microscopy of salivaricin B-treated cells showed a reduction in cell wall thickness together with signs of aberrant septum formation in the absence of visible changes to cytoplasmic membrane integrity.
format Online
Article
Text
id pubmed-4985645
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-49856452016-08-22 New insights into the mode of action of the lantibiotic salivaricin B Barbour, Abdelahhad Tagg, John Abou-Zied, Osama K. Philip, Koshy Sci Rep Article Salivaricin B is a 25 amino acid polycyclic peptide belonging to the type AII lantibiotics and first shown to be produced by Streptococcus salivarius. In this study we describe the bactericidal mode of action of salivaricin B against susceptible Gram-positive bacteria. The killing action of salivaricin B required micro-molar concentrations of lantibiotic whereas the prototype lantibiotic nisin A was shown to be potent at nano-molar levels. Unlike nisin A, salivaricin B did not induce pore formation or dissipate the membrane potential in susceptible cells. This was established by measuring the fluorescence of the tryptophan residue at position 17 when salivaricin B interacted with bacterial membrane vesicles. The absence of a fluorescence blue shift indicates a failure of salivaricin B to penetrate the membranes. On the other hand, salivaricin B interfered with cell wall biosynthesis, as shown by the accumulation of the final soluble cell wall precursor UDP-MurNAc-pentapeptide which is the backbone of the bacterial peptidoglycan. Transmission electron microscopy of salivaricin B-treated cells showed a reduction in cell wall thickness together with signs of aberrant septum formation in the absence of visible changes to cytoplasmic membrane integrity. Nature Publishing Group 2016-08-16 /pmc/articles/PMC4985645/ /pubmed/27526944 http://dx.doi.org/10.1038/srep31749 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Barbour, Abdelahhad
Tagg, John
Abou-Zied, Osama K.
Philip, Koshy
New insights into the mode of action of the lantibiotic salivaricin B
title New insights into the mode of action of the lantibiotic salivaricin B
title_full New insights into the mode of action of the lantibiotic salivaricin B
title_fullStr New insights into the mode of action of the lantibiotic salivaricin B
title_full_unstemmed New insights into the mode of action of the lantibiotic salivaricin B
title_short New insights into the mode of action of the lantibiotic salivaricin B
title_sort new insights into the mode of action of the lantibiotic salivaricin b
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985645/
https://www.ncbi.nlm.nih.gov/pubmed/27526944
http://dx.doi.org/10.1038/srep31749
work_keys_str_mv AT barbourabdelahhad newinsightsintothemodeofactionofthelantibioticsalivaricinb
AT taggjohn newinsightsintothemodeofactionofthelantibioticsalivaricinb
AT abouziedosamak newinsightsintothemodeofactionofthelantibioticsalivaricinb
AT philipkoshy newinsightsintothemodeofactionofthelantibioticsalivaricinb